During the last session, Tscan Therapeutics Inc (NASDAQ:TCRX)’s traded shares were 0.27 million, with the beta value of the company hitting 0.98. At the end of the trading day, the stock’s price was $1.46, reflecting an intraday loss of -5.19% or -$0.08. The 52-week high for the TCRX share is $7.89, that puts it down -440.41 from that peak though still a striking 30.14% gain since the share price plummeted to a 52-week low of $1.02. The company’s market capitalization is $82.62M, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 577.92K shares over the past three months.
Tscan Therapeutics Inc (TCRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.14. TCRX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Tscan Therapeutics Inc (NASDAQ:TCRX) trade information
Tscan Therapeutics Inc (TCRX) registered a -5.19% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.19% in intraday trading to $1.46, hitting a weekly high. The stock’s 5-day price performance is -8.75%, and it has moved by 17.74% in 30 days. Based on these gigs, the overall price performance for the year is -82.62%. The short interest in Tscan Therapeutics Inc (NASDAQ:TCRX) is 2.01 million shares and it means that shorts have 2.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 51.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $3 respectively. As a result, TCRX is trading at a discount of -105.48% off the target high and -105.48% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.41%. While earnings are projected to return -10.90% in 2025, the next five years will return 9.18% per annum.
TCRX Dividends
Tscan Therapeutics Inc is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Tscan Therapeutics Inc (NASDAQ:TCRX)’s Major holders
Tscan Therapeutics Inc insiders own 0.24% of total outstanding shares while institutional holders control 87.82%, with the float percentage being 88.03%. LYNX1 CAPITAL MANAGEMENT LP is the largest shareholder of the company, while 127.0 institutions own stock in it. As of 2024-06-30, the company held over 5.22 million shares (or 4.6062% of all shares), a total value of $30.56 million in shares.
The next largest institutional holding, with 5.0 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 4.4082% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $29.25 million.
